April 6-8, 2026 | Boston, MA – Against a backdrop of major industry acquisitions including AbbVie/Capstan Therapeutics, Eli Lilly & Co/Verve Therapeutics, and now BMS/Orbital Therapeutics, LNPs are catching the eyes of large pharma with their potential to deliver new and innovative cell therapies.
Given this surge of innovation, the LNP team are excited to announce the brand-new agenda for the 5th LNP Formulation & Process Development Summit (April 6-8, 2026 | Boston, MA), the largest industry-led gathering for LNP experts delivering the end-to-end development of LNPs.
Across 3 days and 3 tracks of content, key program highlights include:
- Attracting Investment & Acquisition Opportunities: Amid a surge of high-value deals across the LNP landscape, Capstan Therapeutics and Chiesi Global Rare Diseases are joining a strategic panel to unpack the motivations driving recent acquisitions and partnerships within the LNP community.
- Achieving Extrahepatic Targeting with LNPs: Discover ground-breaking approaches in targeted delivery and innovative formulations enabling extrahepatic applications. Alnylam, Servier and Novartis will share insights to unlock new therapeutic opportunities across diverse disease areas.
- LNPs for Cell & Gene Therapy Delivery: Explore pioneering work on LNP development for cell therapy and gene editing payloads. Brand-new speakers from Yoltech Therapeutics, Innorna and Corner Therapeutics will share their recent work shaping the next generation of cell and gene therapies.
Featured 2026 speakers include:
- Annette Bak, Head, Advanced Drug Delivery, AstraZeneca
- Luis Brito, Vice President, Delivery Platform, Beam Therapeutics
- Adrian Bot, Ex-Chief Scientific Officer & Executive Vice President, Research & Development, Capstan Therapeutics
- Rushit Lodaya, Associate Director, RNA Delivery Sciences, GSK
- Michael Smith, Director, Emerging Technologies, Moderna
- Ching Kim Tye, Head, Drug Product Platform & Early Clinical Development, Sanofi
- Isabelle Gusev, Principal Scientist & Group Leader, Analytical Development, CMC, Tessera Therapeutics
- Peng Zhang, Principal Scientist, Science – Excipients, USP
- Emma Wang, Chief Technology Officer, YolTech Therapeutics
The Full Event Overview, including the complete speaker faculty and session details, is available to download here: https://ter.li/y6ipkw
And as one of our Scientific Advisory Board members put it:
“This Summit showcases the latest advances in LNP formulation, analytical characterization, and process development, addressing key challenges such as extrahepatic targeting, immunogenicity, and scalable manufacturing. The program’s focus on integrating novel lipid chemistries, high-throughput analytics, and automation is important for the translation of RNA and gene editing therapies towards the clinic.”
Annette Bak, Head, Advanced Drug Delivery, AstraZeneca (Scientific Advisory Board Member)